Literature DB >> 356174

Glucose tolerance in relation to skeletal muscle enzyme activities in cancer patients.

K Lundholm, A C Bylund, T Scherstén.   

Abstract

Glucose metabolism and skeletal muscle enzyme activities were studied in nineteen cancer patients and twelve matched controls. The fasting insulin values were normal but the fasting glucose values and the sum of glucose were increased and the sum of insulin was decreased during intravenous glucose tolerance test in the cancer patients. The elimination rate of glucose (k-value) during glucose challenge was, however, not significantly different in cancer patients as compared with that of appropriate controls. The activities of enzymes representative for glycogen turnover, glycolysis, citric acid cycle and respiratory chain were significantly lower in the muscle tissue of cancer patients, while the activity of 3-hydroxyacyl-CoA dehydrogenase, an enzyme in the beta-oxidation of fatty acids, was unchanged and the activity of glucose-6-phosphate dehydrogenase was significantly higher. Rate limiting enzyme activities in muscle tissue, phosphofructokinase and cytochrome c oxidase correlated signficantly with plasma insulin and glucose during glucose challenge. The results point at the possibility of covariating debilitation of pancreatic beta-cells and skeletal muscle enzymes caused by the malignant tumour.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 356174     DOI: 10.1080/00365517709091492

Source DB:  PubMed          Journal:  Scand J Clin Lab Invest        ISSN: 0036-5513            Impact factor:   1.713


  2 in total

1.  Thermic effect and substrate oxidation in response to intravenous nutrition in cancer patients who lose weight.

Authors:  L Lindmark; K Bennegård; E Edén; G Svaninger; M Ternell; K Lundholm
Journal:  Ann Surg       Date:  1986-12       Impact factor: 12.969

Review 2.  Malignant disease: nutritional implications of disease and treatment.

Authors:  S Holmes; J W Dickerson
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.